Original Title: Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. A Systematic Review and Meta-Analysis. Reference: Michael J. Lipinski et al. J Am Coll Cardiol Intv. 2016;9(1):12-24. The authors of this study carried out a systematic review and a meta-analysis to determine the thrombosis risk of the bioresorbable everolimus eluting scaffold ABSORB (Abbott...
Meta-Analysis of Bioresorbable Vascular Scaffolds vs. Everolimus Eluting Stents
Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease. Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for...
Educational Journal N° 103
Edición Especial | Congreso SOLACI-SOCIME 2015, in partnership with TCT 1. Reparación endovascular de la patología de aorta torácica a) Tratando anatomías complejas con TEVAR y EVAR b) El valor de la imagen de la tomografía computada de alta resolución en el diagnóstico y detección de complicaciones en pacientes con síndrome aórtico agudo c) La...
Stent eluidor de sirolimus com polímero absorvível apresenta superioridade em relação a stent eluidor de everolimus com polímero durável
Fundamentos: Ainda há controvérsias em relação à superioridade dos polímeros absorvíveis em relação aos polímeros duráveis, e vários estudos com a comparação entre esses dois modelos vem sendo realizados. Objetivos: Comparar os desfechos clínicos em 3 anos entre o stent eluidor de sirulimus com polímero absorvível MiStent® (APSES) com um stent eluidor de everolimus com...
SORT-OUT V: Similar results of biolimus eluting stent with biodegradable polymer versus sirolimus eluting stent with permanent polymer.
The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and the new device reached the non-inferiority with a MACE rate of 11.2% for...
HATTRICK-OCT: biodegradable polymer struts coverage versus permanent
Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The...
DIRECT: results of drug-eluting stent-on-a-wire after 6 months
This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is made of cobalt chrome and the polymer is bio-degradable. 30 patients were included prospectively and there was angiographic follow-up with IVUS and OCT after 6 months. The reference vessel diameter was 2.69 mm ± 0.48, with a length...
BIOSS: results of the new drug-eluting stent for bifurcations
This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer. It has two separate parts: a larger diameter proximal part and a smaller diameter distal part connected by two 1.2 mm structures. The objective of this study was to test (first in man) the device in bifurcations. We...
Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high...
Educational Journal N° 98
1. ESTUDIOS DE TECNOLOGIAS EN INTERVENCIONES CORONARIAS • RIBS IV – Presentador: Fernando Alfonso • ABSORB II – Presentador: Patrick Serruys 2. ESTUDIOS DE FARMACOLOGIA EN INTERVENCIONES CORONARIAS • ISAR-TRIPLE – Presentador: Nikolaus Sarafoff • SECURITY – Presentador: Antonio Colombo • BRIGHT – Presentador: Yalin Hang 3. ESTUDIOS EN IMÁGENES CORONARIAS • IVUS-CTO – Presentador:...